Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 9;14(6):1400.
doi: 10.3390/cancers14061400.

Updated Prognostic Factors in Localized NSCLC

Simon Garinet  1   2 , Pascal Wang  3 , Audrey Mansuet-Lupo  4 , Ludovic Fournel  5 , Marie Wislez  3 , Hélène Blons  1   2
Affiliations
Review

Updated Prognostic Factors in Localized NSCLC

Simon Garinet et al. Cancers (Basel). .

Abstract

Lung cancer is the most common cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) represents 80% of lung cancer subtypes. Patients with localized non-small cell lung cancer may be considered for upfront surgical treatment. However, the overall 5-year survival rate is 59%. To improve survival, adjuvant chemotherapy (ACT) was largely explored and showed an overall benefit of survival at 5 years < 7%. The evaluation of recurrence risk and subsequent need for ACT is only based on tumor stage (TNM classification); however, more than 25% of patients with stage IA/B tumors will relapse. Recently, adjuvant targeted therapy has been approved for EGFR-mutated resected NSCLC and trials are evaluating other targeted therapies and immunotherapies in adjuvant settings. Costs, treatment duration, emergence of resistant clones and side effects stress the need for a better selection of patients. The identification and validation of prognostic and theranostic markers to better stratify patients who could benefit from adjuvant therapies are needed. In this review, we report current validated clinical, pathological and molecular prognosis biomarkers that influence outcome in resected NSCLC, and we also describe molecular biomarkers under evaluation that could be available in daily practice to drive ACT in resected NSCLC.

Keywords: adjuvant chemotherapy; prognosis; resected NSCLC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of existing prognostic factors in localized NSCLC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Morgensztern D., Ng S.H., Gao F., Govindan R. Trends in Stage Distribution for Patients with Non-Small Cell Lung Cancer: A National Cancer Database Survey. J. Thorac. Oncol. 2010;5:29–33. doi: 10.1097/JTO.0b013e3181c5920c. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Thomas A., Liu S.V., Subramaniam D.S., Giaccone G. Refining the Treatment of NSCLC According to Histological and Molecular Subtypes. Nat. Rev. Clin. Oncol. 2015;12:511–526. doi: 10.1038/nrclinonc.2015.90. - DOI - PubMed
    1. Chaft J.E., Rimner A., Weder W., Azzoli C.G., Kris M.G., Cascone T. Evolution of Systemic Therapy for Stages I–III Non-Metastatic Non-Small-Cell Lung Cancer. Nat. Rev. Clin. Oncol. 2021;18:547–557. doi: 10.1038/s41571-021-00501-4. - DOI - PMC - PubMed